Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036933 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00036933: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00036933 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036933, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies such as QS21 use different ways to stimulate the immune system and stop cancer cells from growing. Combining vaccine therapy with QS21 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with QS21 in treating patients who have prostate cancer.
Interventions
- BIOLOGICAL QS21
- BIOLOGICAL MUC-2-Globo H-KLH conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2002-03 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
What the finished NCT00036933 record still lists
NCT00036933 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which QS21 is the first listed.
NCT00036933 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00036933 about?
NCT00036933 is a clinical study titled "Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies such as QS21 use different ways to stimulate the immune system and stop cancer cells from growing. Combining vaccine therapy with QS21 may kill more tumor cells. PURPOSE: Phase II trial to study...
What is the current status of trial NCT00036933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2002-03. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00036933?
The interventions under investigation include: QS21 (BIOLOGICAL), MUC-2-Globo H-KLH conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00036933?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00036933's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia